• 12/14/2022

    PAION AG convenes extraordinary general meeting for capital reductions by redemption and consolidation of shares

  • 11/30/2022

    PAION AG: CEO Dr. James Phillips leaves the Company as of 30 November 2022, appointment of Supervisory Board member Gregor Siebert as member and new CEO until 30 November 2023

  • 11/15/2022

    PAION AG raises EBITDA forecast for fiscal year 2022

  • 04/27/2022

    PAION GRANTS EXCLUSIVE LICENSE TO CRISTÁLIA FOR DEVELOPMENT AND COMMERCIALIZATION OF REMIMAZOLAM IN LATIN AMERICA

  • 01/07/2022

    ​​​​​​​PAION ASSIGNS CHINESE REMIMAZOLAM PATENTS AND SELLS RELATED FUTURE ROYALTIES FOR EUR 20.5 MILLION TO HUMANWELL HEALTHCARE GROUP